Machine Learning for Personalized Cancer Care: Director’s Seminar Series |
On June 5, 2024 at 12:00 p.m., Adam Yala, PhD will present “Machine Learning for Personalized Cancer Care” for this session of the Distinguished Scientist Director's Seminar Series.
|
Dr. Shiri Gur-Cohen Awarded the UC San Diego Tower Career Development Grant |
Congratulations to Moores Member Dr. Shiri Gur-Cohen for being awarded this $100,000 award to support her groundbreaking research in cancer biology and immunotherapy.
|
ALX Oncology Announces Initiation of Phase II Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer |
Moores Member and Director of the Hanna and Mark Gleiberman Head and Neck Cancer, Dr. Joseph Califano is leading this multi-center, single-arm, open-label Phase II IST to assess a next-generation CD47 blocker’s ability to treat human papillomavirus-mediated oropharyngeal cancer.
|
Clinical Trials Patient Appreciation Day Event |
The inaugural Moores Clinical Trials Patient Appreciation Day is an opportunity to honor the invaluable contributions of patients and their families to medical research.
Tuesday, May 21, 2024
11:30 a.m. to 2:00 p.m.
Moores Goldberg Auditorium
This celebration is for (1) current and past clinical trial participants, (2) those supporting loved ones in trials, and (3) anyone interested in learning about clinical trials. Attendees can connect with others, hear inspiring stories, and enjoy a complimentary lunch.
|
Please Complete the Moores Climate Survey |
The Moores Office of Equity, Diversity, and Inclusion (EDI) has enjoyed meeting so many amazing Moores Members. If you have not yet completed the Moores Climate Survey, then you can do so in two ways: either (1) check your email inbox for an email with the subject Important to Complete: Moores Cancer Center Climate Survey, which contains a unique link to the survey, or (2) click the button below. Although the survey takes less than 5 minutes to complete, the value of your perspective is worth much more.
The Moores Office of EDI hopes that you have been enjoying its Pop-Up events around Moores and is excited to announce the next round of winners.
Post-Survey Sign-Up Drawing (Remote Moores Members can enter to win)
Congratulations! Oscar Valdovinos is the Week 2 Moores Climate Survey online drawing winner and wins a $150 gift card.
In-Person Pop-Up Drawing (Must visit a Pop-Up in person to enter)
Congratulations! Lauren Shaffer and Ricardo Adame are the Pop-Up winners, and each wins a $30 gift card.
Winners—The Office of EDI will be in touch via email 🙂.
If you did not win, then do not worry. Your entries for both drawings remain in the running, and please visit upcoming Pop-Ups happening through May 17, 2024 for more chances to win and pick up treats and Moores goodies.
In addition, there still are more chances to win online and in-person. Just complete the survey, if you have not, or visit a Pop-Up—-locations for these are kept secret and released the day of the event.
These are the dates for the upcoming Pop-Ups:
|
Pop-Up 5—Wednesday, May 15, 2024 (Special Treat)
Pop-Up 6—Friday, May 17th, 2024 (Moores Climate Survey Closes)
|
Equity in Mental Health Series Spring Quarter Events |
The Office of the Vice Chancellor for Equity, Diversity, and Inclusion invites you to join two Spring Quarter events of the Equity in Mental Health series for the 2023–2024 academic year, which target education, tools, and strategies to transform the mental health trajectories of Black college men holistically.
Building a Culture of Care: A Collective Impact Approach for Holistically Supporting Black College Men’s Mental Health
Thursday, May 30, 2024 | 12:00 p.m. to 1:30 p.m.
Liebow Auditorium, Biomedical Sciences Building (BSB), School of Medicine
|
Love Yourz: The Black Men’s Mental Health Mixtape
Thursday, May 30, 2024 | 5:30 p.m. to 7:00 p.m.
Comunidad Room, Cross-Cultural Center
|
|
|
May 14, 2024 | 12:00 p.m.
Leichtag Biomedical Research Building Room 107
|
May 15, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons
|
May 20, 2024 | 8:30 a.m. to 5:00 p.m.
Virtual & In-person, Washington D.C.
|
May 22, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons
|
|
|
Moores Office of Translational Science (OTS) Speed Networking Initiative |
The Moores OTS is accepting requests for its Speed Networking Initiative to advance translational research endeavors. This initiative offers the opportunity to connect with potential collaborators who could lend their expertise to your project. Moores OTS is keen to foster collaboration among Moores Member investigators and facilitate connections that drive impactful translational research. Complete the form below if you seek research collaborators.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
DEADLINE EXTENDED: Cancer Research and Education to Advance Health Equity (CREATE) Partnership, Annual Request for Pre-Pilot Research Project Proposals |
Pre-pilot project funding of up to $40K ($20K per institution) is intended to support teams representing both UC San Diego and SDSU to implement small-scale projects, with the expectation that preliminary findings will support proposals for additional funding. Projects must (1) reflect a true collaboration between SDSU and UC San Diego co-leaders and (2) address one or more of CREATE's priority cancer and cancer disparities areas.
|
Department of Defense (DoD) Funding Announcements |
- The Pancreatic Cancer Research Program (PCARP) released program announcements for the following funding opportunities:
- Focused Pilot Award
- Idea Development Award
- Translational Research Partnership Award
- Learn More
|
- The Prostate Cancer Research Program (PCRP) released program announcements for the following funding opportunities:
- Data Science Award
- Early Investigator Research Award
- Exploration-Hypothesis Development Award
- Idea Development Award
- Physician Research Award
- Learn More
|
Spring 2024 ASPIRE Award: Breaking Ground in Targeting Gastric and Esophageal Tumors |
The Mark Foundation for Cancer Research is partnering with the DeGregorio Family Foundation and the Torrey Coast Foundation, both funders of research focused on gastric and esophageal cancers, to request project proposals for the Spring 2024 ASPIRE Award that not only target tumors of the upper GI tract, but also drive disruptive research to advance the field of gastric and esophageal cancer research and improve patient outcomes.
|
AACR Clinical Oncology Research (CORE) Training Fellowship |
The AACR CORE Training Fellowship provides an industry-academic clinical practicum—a unique opportunity for academic clinicians to train in drug development. This fellowship is designed for early-career clinical scientists who hold a medical degree (MD, DO, or MD-PhD) and are interested in acquiring the knowledge and skills related to drug development from the perspective of the pharmaceutical industry. CORE Fellows gain real-world experience in drug development, clinical research, clinical trial design, and data analysis.
|
|
|
|
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: An International Replication Repair Deficiency Consortium cohort study |
Dennis J. Kuo, MD, MS (Hematologic Malignancies)
|
|
|
| Risk of esophageal cancer in achalasia: A matched cohort study using the Nationwide Veterans Affairs Achalasia Cohort |
The American Journal of Gastroenterology
|
Josh Demb, PhD (Cancer Control Program), Shailja Shah, MD, MPH (Cancer Control Program), and Samir Gupta, MD (Cancer Control Program)
|
|
|
|
RUNX1 C-terminal mutations impair blood cell differentiation by perturbing specific enhancer-promoter networks |
Nathan Jayne, BS (Hematologic Malignancies), Mengdan Liu, BS (Cancer Biology and Signaling), Bing Ren, PhD (Structural and Functional Genomics), and Dong-Er Zhang, PhD (Cancer Biology and Signaling)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
UCSD 807630: Phase I Clinical Trial of Intratumoral Mitazalimab (CD40 Antibody) with Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer |
PI: Rebekah White, MD
NCT: NCT06205849
|
VBP301: Phase I/II Study of Donor-Derived AntiCD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation |
PI: Divya Koura, MD
NCT: NCT05984199
|
EMN28/68284528MMY3005: A Phase III Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible |
PI: Caitlin Costello, MD
NCT: NCT05257083
|
|
|
|
